Spots Global Cancer Trial Database for Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Official Title: Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Study ID: NCT04985357
Conditions
Interventions
Study Description
Brief Summary: The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: Mark Stevens, Ph.D.
Affiliation: Travera Inc
Role: PRINCIPAL_INVESTIGATOR
Name: Robert Kimmerling, Ph.D.
Affiliation: Travera Inc
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
